US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Maze Therapeutics

14.66

-0.8400-5.42%

Volume:57.05K

Turnover:835.58K

Market Cap:642.07M

PE:43.70

High:15.43

Open:15.13

Low:14.20

Close:15.50

Loading ...

Overview Company News Filings

HC Wainwright Initiates Maze Therapeutics at Buy With $34 Price Target

MT Newswires Live

Maze Therapeutics Initiated at Buy by HC Wainwright & Co.

Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock

Maze Therapeutics initiated with a Buy at H.C. Wainwright

Maze Therapeutics participates in a conference call with JPMorgan

Maze Therapeutics Inc. to Participate in H.C. Wainwright 4th Annual Kidney Virtual Conference

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires Live

Maze Therapeutics' Development Strategy Using Genetic Validation Seen as Promising, Wedbush Says

MT Newswires Live

Maze Therapeutics Initiated at Outperform by Wedbush

Maze Therapeutics initiated with an Outperform at Wedbush

Wedbush Initiates Maze Therapeutics at Outperform With $17 Price Target

MT Newswires Live

Maze Therapeutics, Inc. (MAZE) Gets a Buy from TD Cowen

Maze Therapeutics Q1 EPS $(1.15) Up From $(13.91) YoY

Maze Therapeutics Q1 2025: Reports $294.4M Cash Position, R&D Expenses Rise to $27.6M, No Sales or Net Income Data Provided

Press Release: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones

Maze Therapeutics Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

US Market's Undiscovered Gems Featuring ZJK Industrial And 2 More Small Caps

Simply Wall St.

Maze Therapeutics Price Target Maintained With a $19.00/Share by Guggenheim

TD Cowen Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MAZE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":14.66,"timestamp":1753972647798,"preClose":15.5,"halted":0,"volume":57052,"delay":0,"floatShares":16929527,"shares":43797166,"eps":0.33546,"marketStatus":"Trading","change":-0.84,"latestTime":"07-31 10:37:58 EDT","open":15.13,"high":15.43,"low":14.2,"amount":835583.02148,"amplitude":0.079355,"askPrice":14.81,"askSize":3,"bidPrice":14.67,"bidSize":620,"shortable":3,"etf":0,"ttmEps":0.33546,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1753992000000},"marketStatusCode":2,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":15.5,"preHourTrading":{"tag":"盘前","latestPrice":15.18,"preClose":15.5,"latestTime":"09:28 EDT","volume":103,"amount":1620.249946,"timestamp":1753968480023},"postHourTrading":{"tag":"盘后","latestPrice":15.5,"preClose":15.5,"latestTime":"19:45 EDT","volume":155,"amount":2401.27,"timestamp":1753919104035},"volumeRatio":3.932595},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":16929527,"roa":"11.44%","roe":"34.38%","lyrEps":1.421062,"volumeRatio":3.932595,"shares":43797166,"dividePrice":0,"high":15.43,"amplitude":0.079355,"preClose":15.5,"low":14.2,"week52Low":6.71,"pbRate":"2.20","psRate":"3.83","week52High":19.19,"institutionHeld":0,"latestPrice":14.66,"committee":0.990369,"eps":0.33546,"divideRate":0,"volume":57052,"delay":0,"ttmEps":0.33546,"open":15.13,"prevYearClose":16,"prevWeekClose":16.82,"prevMonthClose":12.27,"prevQuarterClose":12.27,"fiveDayClose":16.45,"twentyDayClose":11.86,"sixtyDayClose":10.42},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553521040","title":"HC Wainwright Initiates Maze Therapeutics at Buy With $34 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2553521040","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553521040?lang=en_us&edition=fundamental","pubTime":"2025-07-23 20:10","pubTimestamp":1753272604,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $25.20, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2553214709","title":"Maze Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2553214709","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553214709?lang=en_us&edition=fundamental","pubTime":"2025-07-23 18:37","pubTimestamp":1753267020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2025 06:37 ET (10:37 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2553111092","title":"Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2553111092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553111092?lang=en_us&edition=fundamental","pubTime":"2025-07-23 18:16","pubTimestamp":1753265772,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. (MAZE) has received a new Buy rating, initiated by H.C. Wainwright analyst, Ananda Ghosh. Ananda Ghosh has given his Buy ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-inc-buy-rating-initiated-on-precision-nephrology-potential-and-undervalued-stock-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-inc-buy-rating-initiated-on-precision-nephrology-potential-and-undervalued-stock-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2553127211","title":"Maze Therapeutics initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2553127211","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553127211?lang=en_us&edition=fundamental","pubTime":"2025-07-23 18:10","pubTimestamp":1753265414,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Maze Therapeutics (MAZE) with a Buy rating and $34 price target The company’s MZE782, a first-in-class SLC6A1...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-a-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"gpt_icon":0},{"id":"2551118710","title":"Maze Therapeutics participates in a conference call with JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2551118710","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551118710?lang=en_us&edition=fundamental","pubTime":"2025-07-14 23:20","pubTimestamp":1752506407,"startTime":"0","endTime":"0","summary":"JPMorgan addresses top 10 questions with management on a conference call to be held on July 14 at 12 pm. Webcast Link Published first on TheFly – t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-participates-in-a-conference-call-with-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-participates-in-a-conference-call-with-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765489.SGD","BK4516","LU2237443978.SGD","LU1366192091.USD","JPM","LU0106831901.USD","LU0683600562.USD","IE00BN8TJ469.HKD","MAZE","LU2462157665.USD","LU0048584097.USD","IE0034235295.USD","IE00B1BXHZ80.USD","IE00BKVL7J92.USD","LU1162221912.USD","LU0170899867.USD","LU1551013425.SGD","LU1280957306.USD","IE00BYXW3230.USD","BK4533","LU1145028129.USD","IE00BZ1G4Q59.USD","LU1244550221.USD","LU1914381329.SGD","LU1032466523.USD","LU2237443895.HKD","LU2264538146.SGD","BK4504","LU0006306889.USD","BK4534","LU0203345920.USD","IE00B1XK9C88.USD","LU1629891620.HKD","LU0267386448.USD","BK4207","LU0820561909.HKD","LU1551013342.USD","LU1670628061.USD","LU2023250504.SGD","LU0971096721.USD","LU0211331839.USD","LU0215105999.USD","LU2746668461.USD","IE00BDRTCR15.USD","LU2237443622.USD","LU2756315664.SGD","LU1974910355.USD","LU1119994496.HKD","LU0964807845.USD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2550675994","title":"Maze Therapeutics Inc. to Participate in H.C. Wainwright 4th Annual Kidney Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2550675994","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550675994?lang=en_us&edition=fundamental","pubTime":"2025-07-11 04:05","pubTimestamp":1752177925,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc., a clinical-stage biopharmaceutical company, is set to participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 2:30 p.m. ET. The company will engage in a fireside chat during the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on July 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nNDL4B7SR7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","NDAQ","BK4112","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","BK4588","BK4585","IE00B64PRP62.GBP","BK4007","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2550675491","title":"Maze Therapeutics to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2550675491","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550675491?lang=en_us&edition=fundamental","pubTime":"2025-07-11 04:05","pubTimestamp":1752177900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., July  10, 2025  (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/10/3113673/0/en/Maze-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"gpt_icon":0},{"id":"2550522050","title":"Sector Update: Health Care Stocks Advance in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2550522050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550522050?lang=en_us&edition=fundamental","pubTime":"2025-07-09 01:57","pubTimestamp":1751997449,"startTime":"0","endTime":"0","summary":"Health care stocks rose Tuesday afternoon with the NYSE Health Care Index gaining 0.3% and the Health Care Select Sector SPDR Fund  adding 0.5%.The iShares Biotechnology ETF  climbed 1.3%.In corporate news, Recursion Pharmaceuticals  shares jumped 11% after the company gained full rights to REV102, a drug candidate for hypophosphatasia, after acquiring Rallybio's  interest in the program. Rallybio surged 43%.Pfizer  Chief Corporate Officer Sally Susman will leave the company at the end of the year. Pfizer shares rose 1.1%.ProKidney  shares soared more than sixfold after the company said its investigational therapy rilparencel stabilized kidney function in a group of patients with chronic kidney disease and diabetes who received two injections about three months apart in a phase 2 trial, replicating the dosing regimen of its ongoing phase 3 study.Maze Therapeutics'  development strategy using genetic validation is seen as promising in terms of its target identification strategy and appl","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","PFE.AU","BK4581","MAZE","LU0170899867.USD","SG9999011175.SGD","BK4588","BK4007","BK4533","IE0002270589.USD","LU0225284248.USD","LU1066053197.SGD","BK4534","SG9999002224.SGD","RLYB","SG9999001176.SGD","LU0321505868.SGD","LU1066051498.USD","SG9999001176.USD","SGXZ57979304.SGD","XLV","BK4539","PROK","BK4139","SG9999013999.USD","LU0985481810.HKD","RXRX","LU0058720904.USD","LU0225771236.USD","LU0306806265.USD","LU0456855351.SGD","BK4550","IE00B19Z3B42.SGD","LU0289739699.SGD","LU1023059063.AUD","LU1057294990.SGD","IE00BLSP4452.SGD","LU1883839398.USD","LU0868494617.USD","BK4568","LU1894683264.USD","BK4592","IE00B19Z3581.USD","LU1894683348.USD","SG9999002232.USD","IE00BBT3K403.USD","SG9999003800.SGD","LU0321505439.SGD"],"gpt_icon":1},{"id":"2549525156","title":"Maze Therapeutics' Development Strategy Using Genetic Validation Seen as Promising, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2549525156","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549525156?lang=en_us&edition=fundamental","pubTime":"2025-07-08 22:38","pubTimestamp":1751985502,"startTime":"0","endTime":"0","summary":"Maze Therapeutics'  development strategy using genetic validation is seen as promising in terms of its target identification strategy and application to the nephrology and metabolic disease segments, Wedbush Securities said in a note Tuesday.The firm said the Maze Compass platform using genetic variant analysis to name and validate potential targets is \"impressive.\"Wedbush added that competitor data is a source of external validation, which creates a degree of derisking related to the company's lead assets of MZE829 in APOL1 kidney disease and MZE728 in phenylketonuria.\"Combining multiple near-term catalysts with cash runway into [H2 of 2027], and we see favorable risk/reward for MAZE shares as the stock trades near a [roughly $500 million] valuation,\" the firm said.Wedbush initiated coverage on the company with an outperform rating and $17 price target.Shares of Maze Therapeutics were 5% in recent trading.Price: 12.73, Change: +0.61, Percent Change: +5.03","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","BK4007","BK4596","BK4600","STRK","MAZE","BK4516","BK4595","BK4023"],"gpt_icon":1},{"id":"2549006547","title":"Maze Therapeutics Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2549006547","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549006547?lang=en_us&edition=fundamental","pubTime":"2025-07-08 21:07","pubTimestamp":1751980020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2025 09:07 ET (13:07 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2549654967","title":"Maze Therapeutics initiated with an Outperform at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2549654967","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549654967?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:00","pubTimestamp":1751972422,"startTime":"0","endTime":"0","summary":"Wedbush initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $17 price target Published first on TheFly – the ultimate sour...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-an-outperform-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-initiated-with-an-outperform-at-wedbush-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"gpt_icon":0},{"id":"2549546248","title":"Wedbush Initiates Maze Therapeutics at Outperform With $17 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2549546248","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549546248?lang=en_us&edition=fundamental","pubTime":"2025-07-08 18:53","pubTimestamp":1751972019,"startTime":"0","endTime":"0","summary":"Wedbush Initiates Maze Therapeutics at Outperform With $17 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"gpt_icon":0},{"id":"2535814598","title":"Maze Therapeutics, Inc. (MAZE) Gets a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2535814598","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535814598?lang=en_us&edition=fundamental","pubTime":"2025-05-15 06:45","pubTimestamp":1747262739,"startTime":"0","endTime":"0","summary":"In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maze-therapeutics-inc-maze-gets-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maze-therapeutics-inc-maze-gets-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","TD","BK4207","MAZE","BK4585","BK4566","BK4007","BK4127"],"gpt_icon":0},{"id":"2535298007","title":"Maze Therapeutics Q1 EPS $(1.15) Up From $(13.91) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2535298007","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535298007?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:18","pubTimestamp":1747253896,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(1.15) per share. This is a 91.73 percent increase over losses of $(13.91) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45420733/maze-therapeutics-q1-eps-1-15-up-from-13-91-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2535002461","title":"Maze Therapeutics Q1 2025: Reports $294.4M Cash Position, R&D Expenses Rise to $27.6M, No Sales or Net Income Data Provided","url":"https://stock-news.laohu8.com/highlight/detail?id=2535002461","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535002461?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:03","pubTimestamp":1747253013,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL9X3Kg0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","MAZE"],"gpt_icon":0},{"id":"2535138002","title":"Press Release: Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2535138002","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535138002?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:01","pubTimestamp":1747252860,"startTime":"0","endTime":"0","summary":"MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026. MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025. Strong Balance Sheet with $294.4 Million in Cash and Cash Equivalents, Expected to Provide Cash Runway into H2 2027. SOUTH SAN FRANCISCO, Calif., May 14, 2025  -- Maze Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today reported financial results for the first quarter ended March 31, 2025, and reiterated upcoming milestones.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSGS","BK4007","MAZE"],"gpt_icon":0},{"id":"2535721056","title":"Maze Therapeutics Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2535721056","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535721056?lang=en_us&edition=fundamental","pubTime":"2025-05-13 19:30","pubTimestamp":1747135856,"startTime":"0","endTime":"0","summary":"Maze Therapeutics Inc., a clinical-stage biopharmaceutical company, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20, 2025. Jason Coloma, Ph.D., the CEO, will present a company overview and engage in one-on-one meetings. The presentation will be accessible on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL8Qm6Qn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","BK4007","IE00BKPKM429.USD","NDAQ","BK4588","LU2095319765.USD","IE00B3QW5Z07.USD","BK4585","BK4112","MAZE","LU2210149790.SGD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2528223847","title":"US Market's Undiscovered Gems Featuring ZJK Industrial And 2 More Small Caps","url":"https://stock-news.laohu8.com/highlight/detail?id=2528223847","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528223847?lang=en_us&edition=fundamental","pubTime":"2025-04-18 01:32","pubTimestamp":1744911170,"startTime":"0","endTime":"0","summary":"As the U.S. market grapples with volatility, marked by mixed performances in major indices and concerns over tariffs impacting economic growth, small-cap stocks have become a focal point for investors seeking potential opportunities beyond the turbulence affecting large caps. In this climate, identifying promising small-cap companies like ZJK Industrial involves looking for those with strong fundamentals and resilience to external pressures, making them potential undiscovered gems amid broader market uncertainties.Top 10 Undiscovered Gems With Strong Fundamentals In The United States. Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener.Get an in-depth perspective on ZJK Industrial's performance by reading our health report here.Overview: Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for renal, cardiovascular, related metabolic diseases, and obesity ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-markets-undiscovered-gems-featuring-173250731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MAZE","SWBI","BK4161","ZJK"],"gpt_icon":0},{"id":"2524415108","title":"Maze Therapeutics Price Target Maintained With a $19.00/Share by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2524415108","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524415108?lang=en_us&edition=fundamental","pubTime":"2025-04-02 23:54","pubTimestamp":1743609240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 11:54 ET (15:54 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"gpt_icon":0},{"id":"2524148426","title":"TD Cowen Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524148426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524148426?lang=en_us&edition=fundamental","pubTime":"2025-04-01 22:25","pubTimestamp":1743517520,"startTime":"0","endTime":"0","summary":"In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Maze Therapeutics, Inc. (MAZE – Research Report). The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-maze-therapeutics-inc-maze?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-maze-therapeutics-inc-maze?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","TD","MAZE"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-14","symbol":"MAZE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.15},{"market":"US","date":"2025-03-31","symbol":"MAZE","fiscalQuarterEnding":"2024/12","expectedEps":-7.6,"name":null,"time":"","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"","actualEps":-18.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1753329600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2025-07-30","current":13.272635,"percent":0.91129,"low":6.347498,"twenty":8.250033,"median":9.444315,"eighty":11.228615,"high":14.99285,"avg":9.750682,"sd":2.011015,"marketCap":689367392},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194},{"date":"2025-06-13","current":11.425934,"twenty":7.799992,"median":8.956237,"eighty":10.149874,"marketCap":593451599},{"date":"2025-06-20","current":9.494909,"twenty":7.805949,"median":9.034945,"eighty":10.238649,"marketCap":493156089},{"date":"2025-06-27","current":10.742908,"twenty":7.871903,"median":9.097801,"eighty":10.238649,"marketCap":557975894},{"date":"2025-07-03","current":9.697287,"twenty":7.967493,"median":9.217791,"eighty":10.255514,"marketCap":503667409},{"date":"2025-07-11","current":13.188311,"twenty":8.01948,"median":9.285161,"eighty":10.297295,"marketCap":684987676},{"date":"2025-07-18","current":14.385715,"twenty":8.08904,"median":9.384234,"eighty":10.584212,"marketCap":747179651},{"date":"2025-07-25","current":13.871337,"twenty":8.197097,"median":9.417731,"eighty":10.84241,"marketCap":720463380},{"date":"2025-07-30","current":13.272635,"twenty":8.250033,"median":9.444315,"eighty":11.228615,"marketCap":689367392}],"updateTime":1753959845298}}}